CRISPR Therapeutics Reports Results From Phase 1 CARBON Trial Of CTX110 In Relapsed, Refractory CD19+ B-Cell Malignancies: ‘58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose’
-58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis-
-Durable responses in